Benzinga | Apr 19, 2021 10:06AM EDT

Maxim Group Initiates Coverage On Fennec Pharmaceuticals with Buy Rating, Announces Price Target of $12

Maxim Group analyst Jason McCarthy initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy rating and announces Price Target of $12.